$0.60 EPS Expected for Integra Lifesciences Holdings Corp (IART) This Quarter

Equities research analysts predict that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report $0.60 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Integra Lifesciences’ earnings. The lowest EPS estimate is $0.59 and the highest is $0.61. Integra Lifesciences reported earnings of $0.45 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is scheduled to announce its next earnings results on Wednesday, July 25th.

According to Zacks, analysts expect that Integra Lifesciences will report full-year earnings of $2.41 per share for the current fiscal year, with EPS estimates ranging from $2.38 to $2.44. For the next financial year, analysts expect that the firm will report earnings of $2.74 per share, with EPS estimates ranging from $2.68 to $2.78. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last posted its earnings results on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.09. Integra Lifesciences had a return on equity of 17.90% and a net margin of 5.39%. The firm had revenue of $357.10 million during the quarter, compared to analyst estimates of $349.15 million. During the same period in the previous year, the company earned $0.39 EPS. The company’s revenue for the quarter was up 38.1% on a year-over-year basis.



A number of analysts have recently issued reports on IART shares. JPMorgan Chase & Co. boosted their price objective on Integra Lifesciences from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Wednesday, April 11th. Oppenheimer reissued a “buy” rating on shares of Integra Lifesciences in a research note on Thursday, March 22nd. BTIG Research started coverage on Integra Lifesciences in a research note on Thursday, April 5th. They issued a “neutral” rating and a $56.00 price objective on the stock. Morgan Stanley upped their price target on Integra Lifesciences from $53.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, April 26th. Finally, Citigroup upped their price objective on Integra Lifesciences from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, April 26th. Eleven research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $60.69.

Shares of NASDAQ IART opened at $65.75 on Friday. The company has a current ratio of 2.53, a quick ratio of 1.66 and a debt-to-equity ratio of 1.77. The company has a market capitalization of $5.86 billion, a price-to-earnings ratio of 33.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.65. Integra Lifesciences has a 12 month low of $41.51 and a 12 month high of $67.50.

In related news, VP Daniel L. Reuvers sold 1,000 shares of the business’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $66.97, for a total value of $66,970.00. Following the completion of the sale, the vice president now directly owns 25,009 shares of the company’s stock, valued at approximately $1,674,852.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.10% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. We Are One Seven LLC lifted its stake in Integra Lifesciences by 4,497.1% in the first quarter. We Are One Seven LLC now owns 3,218 shares of the life sciences company’s stock valued at $178,000 after purchasing an additional 3,148 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Integra Lifesciences by 38.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after purchasing an additional 1,054 shares during the period. Coldstream Capital Management Inc. bought a new position in shares of Integra Lifesciences in the first quarter worth $207,000. Stanley Laman Group Ltd. bought a new position in shares of Integra Lifesciences in the first quarter worth $221,000. Finally, Zions Bancorporation bought a new position in Integra Lifesciences in the first quarter valued at $235,000. 79.49% of the stock is owned by institutional investors.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply